Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Nonalcoholic fatty liver].

H Dancygier1

  • 1Medizinischen Klinik II, Klinikum Offenbach.

Versicherungsmedizin
|April 6, 2002
PubMed
Summary
This summary is machine-generated.

Nonalcoholic fatty liver disease (NAFLD) is linked to obesity and diabetes, potentially progressing to cirrhosis. Currently, effective treatments are unavailable, highlighting a critical need for therapeutic advancements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

MMW Fortschritte der Medizin·2016
Same author

Chronic abdominal pain aggravated by eating: diagnosis by video capsule endoscopy.

Gut·2006
Same author

[Gastrointestinal tumor (GIST) of the esophagus in a 34-year-old man: clubbed fingers and alopecia arealis as an early paraneoplastic phenomenon].

Deutsche medizinische Wochenschrift (1946)·2005
Same author

[The 10-minute consultation. Incidental finding -- increased liver values].

MMW Fortschritte der Medizin·2005
Same author

[Whipple disease--a rare systemic disease].

Praxis·2002
Same author

Primary prophylactic therapy of esophageal varices--a literature review.

Hepato-gastroenterology·2002
Same journal

[What do company health insurance plans provide?]

Versicherungsmedizin·2017
Same journal

[Assessment of prescriptive therapies and remedies - Experience and results].

Versicherungsmedizin·2017
Same journal

[The importance of biosimilars medicines for private and statutory health insurance].

Versicherungsmedizin·2017
Same journal

[Can we transfer the mechanisms of the generics market to biosimilars?]

Versicherungsmedizin·2017
Same journal

[Not Available].

Versicherungsmedizin·2016
Same journal

[Not Available].

Versicherungsmedizin·2016
See all related articles

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Context:

  • Nonalcoholic fatty liver disease (NAFLD) is frequently associated with metabolic conditions like obesity, type II Diabetes mellitus, and hyperlipidemia.
  • It can also be linked to chronic viral hepatitis C, presenting a complex etiological profile.
  • The disease spectrum ranges from simple fatty liver to steatohepatitis, fibrosis, and potentially cirrhosis.

Purpose:

  • To summarize the key aspects of Nonalcoholic Fatty Liver Disease (NAFLD).
  • To highlight the association of NAFLD with metabolic disorders and its progression.
  • To underscore the current limitations in therapeutic options for NAFLD.

Summary:

  • NAFLD encompasses a range of liver conditions, from fatty infiltration to cirrhosis, often asymptomatic with mild aminotransferase elevation.

Related Experiment Videos

  • Accurate assessment of inflammation and fibrosis requires liver biopsy, as clinical signs are often minimal.
  • A significant portion of cryptogenic cirrhosis cases may be attributed to nonalcoholic steatohepatitis, indicating its progressive potential.

    • Impact:

    • NAFLD represents a growing public health concern due to its association with metabolic syndrome.
    • Understanding the progression of NAFLD is crucial for identifying at-risk individuals.
    • The lack of proven therapeutic modalities emphasizes the urgent need for research and development in NAFLD treatment.